Development of treatments for sarcopenia: new challenges, opportunities and perspectives
- 16 November 2026
- journal article
- review article
- Published by Springer Nature in Nature Reviews Rheumatology
Abstract
Sarcopenia is characterized by loss of muscle mass, strength and function, and is associated with decline in physical function, falls, fractures and premature mortality. Despite increasing recognition of its clinical and societal burden, progress in translating advances in sarcopenia research into approved pharmacological therapies has remained limited. Potential barriers include heterogeneity in trial design regarding eligibility criteria, follow-up duration and outcomes, as well as limited regulatory harmonization. Given advances in sarcopenia research, the continued absence of approved treatments and the need to integrate perspectives that have emerged since the 2020 ESCEO recommendations for the conduct of sarcopenia clinical trials, this Perspective provides up-to-date expert perspectives on the development of treatments for sarcopenia, informed by discussions held by a working group convened by the World Health Organization Collaborating Centre for Epidemiology of Musculoskeletal Conditions and Ageing. Developments in the definition of sarcopenia, the regulatory landscape and therapeutic approaches are presented, together with considerations for the design of pharmacological trials, including target populations, the selection and assessment of trial outcomes (including digital health measures and patient-reported outcome measures), trial duration, use of biomarkers and patient expectations of treatments.Keywords
This publication has 87 references indexed in Scilit:
- Psychometric Properties of the SarQoL Questionnaire: A Systematic Review and Meta‐AnalysisJournal of Cachexia, Sarcopenia and Muscle, 2025
- Novel Algorithm to Estimate Fat‐Free Muscle Volumes in Women Using the Urinary Deuterated‐Creatine Dilution MethodJournal of Cachexia, Sarcopenia and Muscle, 2025
- Recent Advances in Liquid Chromatography–Mass Spectrometry (LC–MS) Applications in Biological and Applied SciencesAnalytical Science Advances, 2025
- Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory IssuesJournal of Cachexia, Sarcopenia and Muscle, 2025
- BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double‐Blind Randomised Interventional Phase 2b TrialJournal of Cachexia, Sarcopenia and Muscle, 2025
- Leg Muscle Volume, Intramuscular Fat and Force Generation: Insights From a Computer‐Vision Model and Fat‐Water MRIJournal of Cachexia, Sarcopenia and Muscle, 2025
- D3‐creatine dilution, computed tomography and dual‐energy X‐ray absorptiometry for assessing myopenia and physical function in colon cancer: A cross‐sectional studyJournal of Cachexia, Sarcopenia and Muscle, 2023
- Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophyJournal of Cachexia, Sarcopenia and Muscle, 2017
- Validation of the SarQoL®, a specific health‐related quality of life questionnaire for SarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2016
- Welcome to the ICD‐10 code for sarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2016